ArticleDiagnostics (Basel, Switzerland)2022

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report.

Annamaria Catino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.